ArticleCancer chemotherapy and pharmacology2021

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.

Jacob S Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.